Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of My… (NCT03184935) | Clinical Trial Compass
SuspendedPhase 1/2
Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)
Stopped: Others
China40 participantsStarted 2026-12-31
Plain-language summary
The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.
Who can participate
Age range60 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* MDS patients with international prostate symptom score is moderate or severe symptoms
Exclusion Criteria:
* with serious renal function impaired
* with other organ function abnormal: acute hepatitis B, ejection fraction \< 40%, serum bilirubin \> 3mg/dl, liver function tests abnormal, central nervous system disease, mental disease
* bad physical condition (Karmofsky \< 60%)
* without signing informed consent form
* under other therapy that possibly influence MSC security or efficacy
* HIV or other serious disease infection
* Donor: HIV, active hepatitis B/C infection, Syphilitic antibody positive
* Donor/ participants: alcoholism, drug addicted, mental disease